{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:04:06Z","timestamp":1761102246000,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.breast.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T23:01:24Z","timestamp":1484694084000},"page":"93-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history"],"prefix":"10.1016","volume":"32","author":[{"given":"Anita R.","family":"Skandarajah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylie","family":"Shackleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Chin-Lenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Bruce","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2017.01.002_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib2","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2017.01.002_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2017.01.002_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.5694\/mja13.10848","article-title":"Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers","volume":"199","author":"Collins","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.breast.2017.01.002_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-158-8-201304160-00005","article-title":"Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. preventive services task force","volume":"158","author":"Nelson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.breast.2017.01.002_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N\u00a0Engl J Med"},{"year":"2013","series-title":"NCCN clinical practice guidelines in oncology: breast cancer risk reduction version 1","author":"Network NCC","key":"10.1016\/j.breast.2017.01.002_bib7"},{"key":"10.1016\/j.breast.2017.01.002_bib8","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American society of clinical oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib9","series-title":"Excellence NIfHaC","article-title":"Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer","author":"NICE C","year":"2013"},{"year":"2014","series-title":"Risk-reducing medication for women at increased risk of breast cancer due to family history","author":"Australia","key":"10.1016\/j.breast.2017.01.002_bib10"},{"key":"10.1016\/j.breast.2017.01.002_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/fon.13.278","article-title":"Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?","volume":"10","author":"Phillips","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib12","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib13","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.01.002_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian randomized Tamoxifen prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2017.01.002_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.01.002_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.01.002_bib17","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2017.01.002_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.breast.2017.01.002_bib19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2017.01.002_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-012-2041-5","article-title":"Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene","volume":"134","author":"Powles","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.01.002_bib21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/bjc.2014.109","article-title":"Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic","volume":"110","author":"Donnelly","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2017.01.002_bib22","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1897-4287-7-9","article-title":"Australian clinicians and chemoprevention for women at high familial risk for breast cancer","volume":"7","author":"Keogh","year":"2009","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.breast.2017.01.002_bib24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3332\/ecancer.2015.595","article-title":"Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake","volume":"9","author":"DeCensi","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.breast.2017.01.002_bib25","series-title":"San Antonio Breast Cancer Symposium (abstract only)","article-title":"Results from NRG oncology\/NSABP protocol DMP-1:Women's decision-making in breast cancer prevention","author":"Holmberg","year":"2015"},{"key":"10.1016\/j.breast.2017.01.002_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cdp.2007.08.003","article-title":"Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers","volume":"31","author":"Sabatino","year":"2007","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.breast.2017.01.002_bib27","series-title":"Government A","article-title":"Familial risk assessment-FRA-BOC","author":"Australia","year":"2016"},{"key":"10.1016\/j.breast.2017.01.002_bib28","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2017.01.002_bib29","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","article-title":"Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Land","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2017.01.002_bib30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2017.01.002_bib31","first-page":"232","article-title":"Genetic analysis of breast cancer in the cancer and steroid hormone study","volume":"48","author":"Claus","year":"1991","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.breast.2017.01.002_bib32","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1200\/JCO.2002.05.121","article-title":"BRCAPRO validation, sensitivity of genetic testing of BRCA1\/BRCA2, and prevalence of other breast cancer susceptibility genes","volume":"20","author":"Berry","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib33","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancer","volume":"91","author":"Antoniou","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2017.01.002_bib34","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2017.01.002_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/asheducation-2014.1.312","article-title":"Prevention and treatment of venous thromboembolism in patients with cancer","volume":"2014","author":"Lee","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.breast.2017.01.002_bib36","series-title":"Annual AACR international conference on frontiers in cancer prevention research","article-title":"The evaluation of breast cancer chemoprevention uptake in a high-risk cohort","author":"Nimmons","year":"2013"},{"key":"10.1016\/j.breast.2017.01.002_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JOP.2010.000107","article-title":"Implementation in a large health system of a program to identify women at high risk for breast cancer","volume":"7","author":"Owens","year":"2011","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.breast.2017.01.002_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-013-2605-z","article-title":"Providing access to risk prediction tools via the HL7 XML-formatted risk web service","volume":"140","author":"Chipman","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.01.002_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajmg.c.31389","article-title":"Implementation of an electronic genomic and family health history tool in primary prenatal care","volume":"166C","author":"Edelman","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.breast.2017.01.002_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1524-4741.2009.00690.x","article-title":"Identification and management of women at high risk for hereditary breast\/ovarian cancer syndrome","volume":"15","author":"Ozanne","year":"2009","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2017.01.002_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-016-3726-y","article-title":"iPrevent(R): a tailored, web-based, decision support tool for breast cancer risk assessment and management","volume":"156","author":"Collins","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.01.002_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00125817-200007000-00005","article-title":"The gap between practice and genetics education of health professionals: HuGEM survey results","volume":"2","author":"Lapham","year":"2000","journal-title":"Genet Med"},{"key":"10.1016\/j.breast.2017.01.002_bib43","series-title":"Central B","article-title":"Why is understanding breast cancer risk important for women?","author":"Crew","year":"2015"},{"key":"10.1016\/j.breast.2017.01.002_bib44","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1055-9965.EPI-13-1380","article-title":"A\u00a0randomized, controlled trial to increase discussion of breast cancer in primary care","volume":"23","author":"Kaplan","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.breast.2017.01.002_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/GIM.0b013e3181b9b04a","article-title":"Evaluation of a breast\/ovarian cancer genetics referral screening tool in a mammography population","volume":"11","author":"Bellcross","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.breast.2017.01.002_bib46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-148-5-200803040-00004","article-title":"Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model","volume":"148","author":"Tice","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.breast.2017.01.002_bib47","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.01.002_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","article-title":"Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid","volume":"119","author":"Fagerlin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.01.002_bib49","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdt113","article-title":"Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study","volume":"24","author":"Guerrieri-Gonzaga","year":"2013","journal-title":"Ann Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:35:58Z","timestamp":1760776558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977617300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":49,"alternative-id":["S0960977617300024"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2017.01.002","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}